About
33
Publications
3,768
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
176
Citations
Introduction
Skills and Expertise
Current institution
BC Cancer - Kelowna
Current position
- Medical oncologist
Publications
Publications (33)
PURPOSE
This study investigated therapeutic potential of integrated genome and transcriptome profiling of metastatic sarcoma, a rare but extremely heterogeneous group of aggressive mesenchymal malignancies with few systemic therapeutic options.
METHODS
Forty-three adult patients with advanced or metastatic non-GI stromal tumor sarcomas of various...
Background: The BCCA Gastro-intestinal Tumor Group supports one standard of care (SOC) chemotherapy (CT) regimen for metastatic esophago-gastric adenocarcinoma viz. weekly cisplatin and 5FU infusion. All other regimens require Compassionate Access Program (CAP) approval for public funding.
Objectives: To examine response, toxicity and survival aft...
The BC Cancer Agency Gastro-intestinal Tumor Group supports one standard of care (SOC) chemotherapy regimen for metastatic esophagogastric adenocarcinoma-specifically, weekly cisplatin and 5-fluorouracil (5FU) infusion. All other regimens require Compassionate Access Program (CAP) approval for public funding.
We examined response, toxicity, and sur...
Une équipe conjointe de médecins/infirmières s’est efforcée de déterminer si un service de soins téléphoniques géré par des infirmières pouvait être utilisé en toute efficacité et sécurité pour assurer le suivi de patients atteints de cancers hématologiques indolents et chroniques. Les patients se présentant à leur visite de suivi régulière ont été...
A physician/nurse collaborative team sought to determine whether a nurse-led telephone clinic (Teleclinic) could effectively and safely be used to follow patients with indolent and chronic hematological malignancies. Patients seen at their routine follow-up visit were assessed for eligibility for the Teleclinic, then referred to the pilot Teleclini...
Severe 5-FU toxicity in adjuvant therapy of colorectal cancer may require change of therapy. We retrospectively explored the safety and efficacy of adjuvant raltitrexed in patients intolerant of 5-FU.
Over a 5 year period, patients who received 5-FU and subsequent raltitrexed therapy were identified.
There were 44 patients, (39 stage III). Median n...
15158
Background: The BCCA GI Tumor Group supports 1 CT regimen for MEGA: weekly 5FU-cisplatin [FUC] (Shah, ASCO 1992, A530) for first line SOC CT. All other regimens (PC) require “undesignated” approval for public funding. Reasons for PC requests include prior CT, results of modern CT trials, and contra-indications to FUC. Objectives: to examine r...
6538
Background: At the BC Cancer Agency -CSI we are challenged to provide systemic cancer care to a population of 720,000 widely dispersed over 250,000 square kilometers. Video-link technology (VT) has been used at our centre since April 2004 to help provide distant care and prevent patient and physician travel. Methods: Patients gave consent for...
3571
Background: Severe 5FU toxicity in AT of CRC may require discontinuation or change of therapy. RAL, a TS inhibitor, has different toxicity but similar efficacy in metastatic CRC. Excess mortality from RAL in the PETACC trial has limited its role in CRC AT. RAL AT (3 mg/m ² IV q3w) was offered at BCCA to pts with demonstrated intolerance to bol...
This is the third in a series of articles relating results from a line of research whose intent was to construct a complete history of patient interactions with the health care system using available data sources for all patients diagnosed in 1990 with a primary breast, colorectal, or lung tumour in Manitoba. This article presents details of the de...
Il s’agit du troisieme article de recherche d’une serie qui visait a elaborer un historique complet des interactions des patients avec le systeme des soins de sante en utilisant les sources de donnees disponibles pour tous les patients du Manitoba diagnostiques, en 1990, d’une tumeur primitive au sein, au colon-rectum ou au poumon. Cet article four...
Il s’agit du deuxième article de recherche d’une série qui visait à élaborer un historique complet des interactions des patients avec le système des soins de santé. Cet article fournit des détails sur les méthodes mises au point pour recueillir et assembler les renseignements épars relatifs à l’historique des interventions (trajectoire) que subit u...
Il s’agit du premier article d’une série rapportant les résultats detravaux de recherche qui élaboraient, à partir des sources de données disponibles, un historique complet des interactions avec le système de santé de tous les patients diagnostiqués en 1990, au Manitoba, de tumeurs primitives mammaires, colorectales ou pulmonaires et ce, à partir d...
This is the second in a series of articles from a line of research whose intent was to construct a complete history of interactions with the health care system. This paper provides details of the methods developed to collect and collate the scattered information regarding the event history (trajectory) that a cancer patient experiences in traveling...
This is the first in a series of articles relating results from research which constructed a complete history of interactions with the health care system from available data sources for all patients diagnosed in 1990 with primary breast, colorectal, or lung tumours in Manitoba from one year prior to diagnosis through to two years post-diagnosis. Th...
Unlabelled:
BACKGROUND/PATIENTS AND METHODS: Thirty-two patients with recurrent head and neck cancer (HNC) following radiotherapy and/or surgery were treated with eniluracil (10 mg/m2) and 5-fluorouracil (5-FU) (1 mg/m2) (E5F) orally twice daily for 28 days followed by a seven-day treatment free period. Thirty-five-day cycles were repeated until d...
Question What is the role of irinotecan combined with 5-fluorouracil and leucovorin as first-line systemic therapy in the management of metastatic colorectal cancer? Perspectives Evidence was selected and reviewed by two members of the Gastrointestinal Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative and by...
Question: What is the role of irinotecan (Camptosar(TM), CPT-11) in the second-line treatment of metastatic colorectal carcinoma? Perspective: Evidence was collected and reviewed by one member of the Gastro-intestinal Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative. The Gastro-intestinal Cancer DSG comprise...
Question: What is the role of post-operative adjuvant radiotherapy or chemotherapy, or both, for patients with resected stage II or stage III rectal cancer in improving survival and delaying local recurrence? Perspectives: Evidence was reviewed and summarised by four members of the Gastro-intestinal Cancer Disease Site Group (DSG) of Cancer Care On...
This multicenter phase II trial investigated the efficacy and toxicity of a combination of the novel intracellular histamine antagonist, N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl (DPPE), and doxorubicin in patients with anthracycline-naïve metastatic breast cancer. Preclinical models and early single institutional studies suggested DPPE...
In a multicenter phase II study, 30 patients with unresectable, locally advanced or metastatic squamous cell or adenocarcinoma of the esophagus were treated with folinic acid 200 mg/m2/d, 5-FU 300 mg/m2/d, and cisplatin 20 mg/m2/d intravenously for 5 days every 4 weeks. Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (...
Question: What is the role of raltitrexed (Tomudex®) in the management of metastatic colorectal cancer?. Perspective: Evidence was selected, reviewed, and synthesised by medical oncologists who are members of the Gastro-intestinal Cancer Disease Site Group (DSG) of the Cancer Care Ontario Practice Guidelines Initiative. The Gastro-intestinal Cancer...
Mice that are immune-suppressed by thymectomy and by sequential treatment with 1-beta-D-arabinofuranosylcytosine and whole body irradiation may be used as hosts for generation of human tumor xenografts. We have studied the effect of various additional methods of immune suppression on the formation of tumors after i.m. injection and on the formation...
We investigated the influence of the poly(ADP-ribose) polymerase inhibitor 3-aminobenzamide (ABA) on induction of phenotypic markers of granulocyte differentiation by retinoic acid and markers of macrophage differentiation by TPA in HL-60 cells. The differentiation of HL-60 cells towards the granulocyte lineage was assessed by hexose monophosphate...
